Diffuse Midline Glioma
📧 Sign up to get email alerts when something new happens for Diffuse Midline Glioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors [Phase 1]
Phase 1 clinical trial evaluating B7-H3–specific CAR T cell therapy delivered locoregionally for diffuse intrinsic pontine glioma/diffuse mi…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: H3K27M-specific Immune Effector Cells Targeting DMG/DIPG [Phase 1, Phase 2]
A Phase 1/2 clinical trial of H3K27M-targeted immune effector cells for diffuse midline glioma and DIPG is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Oral ONC201 in Adult Recurrent Glioblastoma [Phase 2]
Phase 2 trial of oral ONC201 in adult recurrent glioblastoma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Oral AMXT 1501 Dicaprate in Combination With IV DFMO [Phase 1, Phase 2]
A Phase 1/2 trial of oral AMXT 1501 dicaprate in combination with IV DFMO has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG [Phase 2]
Phase 2 study of SONALA-001 with Exablate 4000 Type 2.0 for diffuse intrinsic pontine glioma and diffuse midline glioma has been suspended.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.